Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
CVS Health Corp.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
Lower valuation, weak fundamentals
Get notified when we ship meaningful updates. No spam, no daily noise.
2 of 5 met · composite in line with peers
Business quality, valuation against the sector, and position in the 52-week range — whether they line up or not.
Stable quality
Profitability
3/4
Debt & liquidity
1/3
Efficiency
2/2
Cheap on price, strained on fundamentals — that tension defines the CVS picture. P/B sits -73% below the sector median at 1.6×, and FCF yield of 9.7% runs well above the median 3.9%, so the valuation case has real weight. The balance sheet pulls the other way: Debt/EBITDA of 6.5× exceeds the sector median 3.1× by +113%, and operating margin of 1.2% trails the sector median 19.1% by -94% — both land in the bottom quartile for the sector. The F-Score of 6/9 reflects that split, with the liquidity and balance-sheet components dragging against solid efficiency marks. Consensus and the realized three-year EPS CAGR are broadly aligned here, which is the less common outcome; the forward PEG reads as reasonable, and the beat rate over the last eight quarters is strong — the most recent quarter came in -62.0% ahead of estimates.
| Ticker | Name | F-Score | ROE | Revenue YoY | Op. margin |
|---|---|---|---|---|---|
| ABBV | AbbVie | 8/9 | 15 367% |
Quarter-by-quarter classification · a retrospective read by the current logic · not a price forecast
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice. The method did not see these quarters in real time; this is the current logic applied to past reports.
The market prices in earnings growth; analyst sentiment is strengthening; has mostly beaten consensus.
Price against next year's expected earnings. The forward P/E already carries analyst optimism — read it alongside the “Versus consensus” line.
A forward P/E below the current one means the market expects earnings to grow; above it, to fall. The historical growth is realized figures from SEC filings, not a forecast.
The three-month change in the share of positive analyst ratings. This is sentiment, not an earnings-estimate revision, and not a call to act.
When CVS reports on 2026-10-27, track revenue year over year and operating margin against the current 19.1% sector median gap. The F-Score profitability block sits at 3/4, so check whether cash generation from operations holds or slips further.
On SEC EDGAR, open CVS Health's most recent 10-K and read the Management's Discussion section for commentary on the 3.06× Debt/EBITDA load and the drivers behind the operating margin that runs 94% below the sector median. The risk factors section will detail refinancing timelines and pharmacy reimbursement pressures that bear directly on those figures.
From the same-sector table in section 06, pick two or three companies yourself and line up Debt/EBITDA against FCF yield. CVS carries a 3.95% FCF yield alongside a 3.06× debt load — seeing where those two metrics sit for peers you select will give a cleaner sense of the trade-off across the sector.
Steps you can check yourself, based on the figures in this brief.
Piotroski F-Score: nine binary tests of financial strength from the annual report. A ✓ marks a test passed, a dot (·) a test failed.
Over 4 years: -15%-23%-39%+23%
Over 4 years: 4.143.244.626.53
Over 4 years: +10%+11%+4%+8%
The context on the right shows how each figure compares with the sector median. The trend below tracks the change over recent fiscal years.
Beat consensus in 7 of 8 recent quarters — the company clears estimates regularly (consensus is often set conservatively).
Last quarter's EPS against consensus, plus the estimated date of the next report.
| +9% |
| 25% |
| ABT | Abbott | 6/9 | 13% | +6% | 18% |
| AMGN | Amgen | 7/9 | 106% | +10% | 25% |
| BMY | Bristol-Myers Squibb | 8/9 | 41% | -0% | — |
| CVS | CVS Health Corp. | 6/9 | 2% | +8% | 1% |
| DHR | Danaher | 5/9 | 7% | +3% | 19% |
| GILD | Gilead Sciences | 8/9 | 40% | +2% | 34% |
| ISRG | Intuitive Surgical | 6/9 | 17% | +21% | 29% |
| JNJ | Johnson & Johnson | 4/9 | 35% | +6% | — |
| LLY | Eli Lilly | 7/9 | 101% | +45% | — |
| MRK | Merck | 4/9 | 37% | +1% | — |
| PFE | Pfizer | 5/9 | 9% | -2% | — |
| TMO | Thermo Fisher | 5/9 | 13% | +4% | 17% |
| UNH | UnitedHealth | 7/9 | 18% | +12% | 4% |
A sample of 14 companies in the sector including the target, alphabetical, unranked. Data from the latest SEC annual reports.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
A simplified retrospective read: no analyst forecast (not available historically); the source is the annual report as of the date, so neighbouring quarters can rest on the same data. Quarters with the same classification in a row are merged into one row — each row is one change in the read, not a separate quarter. One ticker is an illustration of the classification logic, not statistics. How we calculate →
The last few quarters are recent context, not a fixed rate. Consensus for near quarters is set low, so companies clear it routinely; over long horizons the forecasts run the other way, too high.
A description of what the market and analysts expect. Not a price forecast and not investment advice. Analyst forecasts run systematically optimistic over long horizons — read them with that discount.